These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8056700)

  • 21. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
    Hermsen ED; Hanson M; Sankaranarayanan J; Stoner JA; Florescu MC; Rupp ME
    Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.
    Ingram PR; Lye DC; Tambyah PA; Goh WP; Tam VH; Fisher DA
    J Antimicrob Chemother; 2008 Jul; 62(1):168-71. PubMed ID: 18334494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between vancomycin-associated nephrotoxicity and the number of combined nephrotoxic agents.
    Ueki T; Sanematsu E; Furuya Y; Shinohara Y; Murakami Y; Miyazaki A; Sakamoto Y; Nakashima MN; Nakashima M
    Pharmazie; 2020 Jun; 75(6):279-283. PubMed ID: 32539926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study.
    Matson KL; Shaffer CL; Beck GL; Simonsen KA
    Pharmacotherapy; 2015 Mar; 35(3):337-43. PubMed ID: 25756622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older.
    Wang Y; Dai N; Wei W; Jiang C
    Clin Interv Aging; 2021; 16():1023-1035. PubMed ID: 34103905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of vancomycin nephrotoxicity when administered to outpatients as a continuous 24-hour infusion.
    Chambers ST; Long M; Gardiner SJ; Chin PKL; Yi M; Dalton SC; Drennan PG; Metcalf SCL
    Int J Antimicrob Agents; 2020 Jun; 55(6):105972. PubMed ID: 32298746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nephrotoxicity of vancomycin, alone and with an aminoglycoside.
    Rybak MJ; Albrecht LM; Boike SC; Chandrasekar PH
    J Antimicrob Chemother; 1990 Apr; 25(4):679-87. PubMed ID: 2351627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia.
    Fullmer A; McCue D; Feng C
    J Oncol Pharm Pract; 2014 Dec; 20(6):403-8. PubMed ID: 24177356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy.
    Pauly DJ; Musa DM; Lestico MR; Lindstrom MJ; Hetsko CM
    Pharmacotherapy; 1990; 10(6):378-82. PubMed ID: 2287556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous Vancomycin Associated With the Development of Nephrotoxicity in Patients With Class III Obesity.
    Choi YC; Saw S; Soliman D; Bingham AL; Pontiggia L; Hunter K; Chuang L; Siemianowski LA; Ereshefsky B; Hollands JM
    Ann Pharmacother; 2017 Nov; 51(11):937-944. PubMed ID: 28709394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
    Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH
    Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans.
    Prabaker KK; Tran TP; Pratummas T; Goetz MB; Graber CJ
    J Hosp Med; 2012 Feb; 7(2):91-7. PubMed ID: 22086511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit.
    Cies JJ; Shankar V
    Pharmacotherapy; 2013 Apr; 33(4):392-400. PubMed ID: 23471688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
    Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective Analysis of Vancomycin Nephrotoxicity in Elderly Chinese Patients.
    Liu Y; Yin Y; Liu XZ; Yao HJ; Li LX; Chen JH; Chen T; Lu XT; Bu SH; Zhang J
    Pharmacology; 2015; 95(5-6):279-84. PubMed ID: 25997622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-Treatment Serum C-Reactive Protein Level Is An Independent Risk Factor for Development of Nephrotoxicity in Patients Receiving High-Dose Vancomycin.
    He J; Mao EQ; Jing F; Jiang HT; Yang WH; Chen EZ
    Pharmacology; 2016; 97(5-6):294-300. PubMed ID: 26919511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy.
    Nahata MC
    Chemotherapy; 1987; 33(4):302-4. PubMed ID: 3608631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction of a risk prediction model of vancomycin-associated nephrotoxicity to be used at the time of initial therapeutic drug monitoring: A data mining analysis using a decision tree model.
    Imai S; Yamada T; Kasashi K; Niinuma Y; Kobayashi M; Iseki K
    J Eval Clin Pract; 2019 Feb; 25(1):163-170. PubMed ID: 30280456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for Amphotericin B-associated nephrotoxicity.
    Fisher MA; Talbot GH; Maislin G; McKeon BP; Tynan KP; Strom BL
    Am J Med; 1989 Nov; 87(5):547-52. PubMed ID: 2816970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.
    Mousavi M; Zapolskaya T; Scipione MR; Louie E; Papadopoulos J; Dubrovskaya Y
    Pharmacotherapy; 2017 Mar; 37(3):379-385. PubMed ID: 28079263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.